Nanoparticles for the delivery of genes and drugs to human hepatocytes

Nature Biotechnology

Volumn 21, Issue 8, 2003, Pages 885-890

  Yamada, Tadanori ^a,b   Iwasaki, Yasushi ^c   Tada, Hiroko ^d   Iwabuki, Hidehiko ^a,e   Chuah, Marinee K L ^f   VandenDriessche, Thierry ^f   Fukuda, Hideki ^b   Kondo, Akihiko ^b   Ueda, Masakazu ^c,g   Seno, Masaharu ^d   Tanizawa, Katsuyuki ^a   Kuroda, Shun'ichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^g Beacle Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; NANOSTRUCTURED MATERIALS; PROTEINS; VIRUSES;

DRUG DELIVERY SYSTEMS;

GENETIC ENGINEERING;

BLOOD CLOTTING FACTOR 9; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; GENE TARGETING; GENE TRANSFER; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER CELL CULTURE; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS PARTICLE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DNA; DRUG DELIVERY SYSTEMS; ELECTROPORATION; FEASIBILITY STUDIES; GENE TARGETING; GENE THERAPY; HEPATOCYTES; HUMANS; MALE; MICE; MICROSPHERES; MOLECULAR SEQUENCE DATA; NANOTECHNOLOGY; NEOPLASMS; PARTICLE SIZE; TRANSFECTION; VIRAL ENVELOPE PROTEINS;

ANIMALIA; HEPATITIS B VIRUS;

EID: 12444252075     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt843     Document Type: Article

References (33)

1. Verma, I.M. & Sonia, N. Gene therapy: promises, problems, and prospects. Nature 389, 239-242 (1997).
2. Friedmann, T. Human gene therapy: an immature genie, but certainly out of the bottle. Nat. Med. 2, 144-147 (1996).
3. VandenDriessche, T. et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100, 813-822 (2002).
4. Chuah, M.K. et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101, 1734-1743 (2003).
5. Marshal, E. Viral vectors still pack surprises. Science 294, 1640 (2001).
6. Marshal, E. Gene therapy death prompts review of adenovirus vector. Science 286, 2244-2245 (1999).
7. Buckley, R.H. Gene therapy for SCID - a complication after remarkable progress. Lancet 360, 1185-1186 (2002).
8. Fox, J.L. Investigation of gene therapy begins. Nat. Biotechnol. 18, 143-144 (2000).
9. Heermann, K.H. et al. Large surface proteins of hepatitis B virus containing the pre-S sequence. J. Virol. 52, 396-402 (1984).
10. Kuroda, S., Itoh, Y., Miyazaki, T., Otaka-Imai, S. & Fujisawa, Y. Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeast. Gene 78, 297-308 (1989).
11. Fujisawa, Y., Kuroda, S., Van Eerd, P.M., Schellekens, H. & Kakinuma, A. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 8, 192-198 (1990).
12. Kuroda, S., Fujisawa, Y., lino, S., Akahane, Y. & Suzuki, H. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2+S) protein particles (a third generation vaccine). Vaccine 9, 163-169 (1991).
13. Kuroda, S., Otaka, S., Miyazaki, T., Nakao, M. & Fujisawa, Y. Hepatitis B virus envelope L protein particles, synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J. Biol. Chem. 267, 1953-1961 (1992).
14. Yamada, T. et al. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-Sl+pre-S2+S) protein. Vaccine 19, 3154-3163 (2001).
15. Marion, P.L., Salazar, F.H., Alexander, J.J. & Robinson, W.S. Polypeptides of hepatitis B virus surface antigen produced by a hepatoma cell line. J. Virol. 32, 796-802 (1979).
16. Neurath, A.R., Kent, S.B., Stick, N. & Parker, K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-436 (1986).
17. Le Seyec, J., Chouteau, P., Cannie, I., Guguen-Guillouzo, C. & Gripon, P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73, 2052-2057 (1999).
18. Kobayashi, M. et al. Recombinant hepatitis B virus surface antigen carrying the pre-S2 region derived from yeast: purification and characterization. J. Biotechnol. 8, 1-22 (1988).
19. Chuah, M.K. et al. Gene therapy for hemophilia. J. Gene Med. 3, 3-20 (2001).
20. VandenDriessche, T., Collen, D. & Chuah, M.K.L. Viral vector-mediated gene therapy for hemophilia. Curr. Gene Ther. 1, 301-305 (2001).
21. Follenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C. & Naldini, L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13, 243-260 (2002).
22. Itoh, Y., Kuroda, S., Miyazaki, T., Otaka, S. & Fujisawa, Y. Identification of polymerized-albumin receptor domain in the pre-S2 region of hepatitis B virus surface antigen M protein. J. Biotechnol. 23, 71-82 (1992).
23. Smith, K.R. Gene transfer in higher animals: theoretical considerations and key concepts. J. Biotechnol. 99, 1-22 (2002).
24. Ishikawa, H. et al. Utilization of variant-type of human α-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma. Gene Ther. 6, 465-470 (1999).
25. Carman, W.F. et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325-329 (1990).
26. Chiou, H. L., Lee, T.S., Kuo, J., Mau, Y.C., and Ho, M.S. Altered antigenicity of 'a' determinant variants of hepatitis B virus. J. Gen. Virol. 78, 2639-2645 (1997).
27. del Canho, R. et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 15, 1624-1630 (1997).
28. Michel, M.L et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA 85, 7957-7961 (1988).
29. Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127 (2002).
30. Yoshida, J., Mizuno, M. & Yagi, K. Efficient transfection of human interferon-β gene to human glioma cells by means of cationic multilamellar liposomes coupled with a monoclonal antibody. J. Neurooncol. 19, 269-274 (1994).
31. Sonveaux, N., Thines, D. & Ruysschaert, J.M. Characterization of the HBsAg particle lipid membrane. Res. Virol. 146, 43-51 (1995).
32. Murayama, Y. et al. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human α-fetoprotein gene. J. Surg. Oncol. 70, 145-149 (1999).
33. Inoue, S., Ogawa, H., Yasuda, K., Umesono, K. & Tsuji, F.I. A bacterial cloning vector using a mutated Aequorea green fluorescent protein as an indicator. Gene 189, 159-162 (1997).